Welcome to our dedicated page for Scienture Holdings news (Ticker: SCNX), a resource for investors and traders seeking the latest updates and insights on Scienture Holdings stock.
Scienture Holdings, Inc. (NASDAQ: SCNX) generates news that centers on specialty pharmaceutical product launches, commercialization milestones, financing activities and corporate governance developments. Through its wholly owned subsidiary Scienture, LLC, the company focuses on novel specialty products that address unmet market needs, and its announcements frequently highlight progress in bringing these therapies to patients, physicians and healthcare institutions.
Recent Scienture news has emphasized Arbli™, which the company describes as the first and only oral liquid formulation of losartan approved by the U.S. FDA and the first FDA-approved, ready-to-use oral suspension formulation of losartan potassium. Updates have covered the start of commercial sales and fulfillment of initial orders, availability of Arbli™ through full-line wholesalers nationwide, multiple group purchasing organization (GPO) agreements providing access to thousands of healthcare institutions, and the addition of Arbli™ to formularies of major national health plans.
Another major news theme is REZENOPY™ (naloxone HCl) Nasal Spray 10 mg, which Scienture presents as the highest dosage naloxone HCl nasal spray approved by the FDA for emergency treatment of known or suspected opioid overdose. Company releases have described exclusive U.S. commercialization rights, FDA approval, and the issuance of an Orange Book-listable U.S. patent that may support the product’s U.S. commercialization.
Investors following SCNX news can also expect updates on SEC filings, equity distribution arrangements, secured financing transactions, conversion of prior debentures into common stock, and notices related to Nasdaq listing requirements. Governance and shareholder matters, such as annual meeting proposals, equity incentive plan amendments and bylaw changes, are reported through both press releases and current reports on Form 8-K. This news feed offers a centralized view of Scienture’s commercial progress, regulatory developments and capital markets activity.
Scienture (NASDAQ: SCNX) received a 180-calendar day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement, extending the deadline to October 12, 2026. The company’s common stock will continue trading on the Nasdaq Capital Market.
Nasdaq found Scienture met all other listing criteria except the bid price; the company may cure the deficiency by raising the bid above $1.00 for ten consecutive business days or, if necessary, by effecting a reverse stock split. Scienture cited recent commercial momentum, including FDA approval and launch activity.
Scienture (NASDAQ: SCNX) provided its 2025 annual shareholder update on April 6, 2026, highlighting commercialization progress and financial results. Revenue rose 216% to $431,609; gross margin expanded to 76.8% (+7,240 bps). The company launched Arbli in Sept 2025 and expects to launch REZENOPY in Q2 2026.
Year-end cash was ~$6.7M with positive working capital ~$5.2M; net loss from continuing operations was ~$41.5M including a $26.3M non-cash impairment. Nasdaq minimum bid compliance action deadline is April 13, 2026.
Scienture (NASDAQ: SCNX) reported 2025 results on March 30, 2026, driven by the commercial launch of Arbli™. Net revenue rose 216% to $431,609 and gross margin expanded 7,240 basis points to 76.8%. The year included a $26.3M one-time, non-cash impairment, leaving net loss from continuing operations of $41.5M. As of December 31, 2025, cash totaled $6.7M with $5.2M positive working capital. Operationally, Scienture secured multiple PBM/GPO and formulary agreements for Arbli™ and REZENOPY™, obtained Orange Book-listable patents for both products, and established a BlinkRx collaboration to support patient access.
Scienture (NASDAQ: SCNX) announced GPO agreements giving REZENOPY™ (naloxone HCl) Nasal Spray 10 mg access to more than 5,000 healthcare institutions, representing potential penetration of roughly 60% of the U.S. institutional market. REZENOPY™ is the highest-dose FDA-approved naloxone nasal spray.
IQVIA (MAT Jan 2026) shows the U.S. naloxone market at $141M annual sales with 9.4M prescription units, highlighting a defined commercial opportunity for broader institutional adoption through hospitals, EMS, and rehabilitation centers.
SCIENTURE (NASDAQ: SCNX) provided a commercial update on ARBLI™, the first FDA-approved ready-to-use oral suspension of losartan, reporting payer and distribution wins that expand access across retail, institutional and managed-care channels.
Key achievements include PBM-led GPO rebates, Institutional GPO deals covering >2,500 facilities, formulary inclusion for >100 million covered lives, a BlinkRx collaboration, reaffirmed REZENOPY™ commercial launch in Q2 2026, and a year-end cash position of approximately $7.0 million after debt reduction.
SCIENTURE (NASDAQ: SCNX) announced issuance of U.S. Patent No. 12,514,854 B2, an Orange Book-listable patent covering REZENOPY™ (naloxone HCl) Nasal Spray 10 mg, effective Jan 6, 2026 and expiring Feb 5, 2041. Scienture holds exclusive U.S. commercialization rights under a March 2025 agreement with Summit, which will manufacture and supply the product. REZENOPY™ received FDA approval on Apr 19, 2024 and is the highest-dosage FDA-approved naloxone nasal spray. IQVIA (MAT Sep 2025) reports U.S. naloxone sales of approximately $154 million and 9.3 million units, highlighting the market opportunity.
SCIENTURE (NASDAQ: SCNX) provided an update on the commercial launch of REZENOPY® (naloxone HCl) Nasal Spray 10 mg, the highest-strength FDA-approved naloxone product. Scienture acquired exclusive U.S. commercialization rights in March 2025 and notes FDA approval occurred on April 19, 2024. IQVIA data (MAT September 2025) shows the U.S. naloxone market at approximately $154 million in annual sales and 9.3 million units annually.
Manufacturing is reported to be on track with product readiness expected in Q1 2026, wholesale loading in Q1 2026, and commercial availability beginning in early Q2 2026.
SCIENTURE (NASDAQ: SCNX) announced a strategic collaboration with BlinkRx to expand national access to Arbli™, the first FDA-approved ready-to-use oral suspension of losartan potassium. Arbli™ is expected to be available on the BlinkRx platform in Q1 2026. The U.S. losartan market totals about $245M in annual sales with roughly 71 million prescriptions (IQVIA MAT Sept 2025). BlinkRx reports it helps 52% more patients start therapy and keeps them on medication 40% longer, which Scienture says may increase starts, duration, and affordability for patients needing suspension formulations.
SCIENTURE HOLDINGS (NASDAQ: SCNX) announced management will participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference on December 9–10, 2025. Narasimhan Mani, President and co-CEO, will present at 2:00 PM ET on December 9. Shankar Hariharan, Executive Chairman and co-CEO, will join one-on-one investor meetings on December 10. A live webcast of the presentation is available at the conference link and a replay will be posted on the company’s investor site under Events and Presentations. The two-day event features Day 1 webcasts and Day 2 one-on-one investor meetings for pre-qualified investors.
SCIENTURE (NASDAQ: SCNX) reported Q3 2025 results and a business update on November 13, 2025. The company launched Arbli™, the first FDA-approved ready-to-use liquid formulation of losartan, and began commercial sales.
Q3 2025 vs Q3 2024: net revenue rose from ~$65K to $590K, and gross profit increased from ~$4K to $575K. Arbli was added to national payor formularies covering >100 million lives and secured GPO agreements reaching >2,500 institutions (~20% of U.S. institutional market). Post-quarter, the company reduced outstanding debt and reported cash of >$8 million as of November 13, 2025. Management plans a commercial launch of REZENOPY® in Q1 2026.